The impact of acute air pollution fluctuations on bronchiectasis pulmonary exacerbation: a case-crossover analysis
- PMID: 29903857
- DOI: 10.1183/13993003.02557-2017
The impact of acute air pollution fluctuations on bronchiectasis pulmonary exacerbation: a case-crossover analysis
Abstract
In bronchiectasis, exacerbations are believed to be triggered by infectious agents, but often no pathogen can be identified. We hypothesised that acute air pollution exposure may be associated with bronchiectasis exacerbations.We combined a case-crossover design with distributed lag models in an observational record linkage study. Patients were recruited from a specialist bronchiectasis clinic at Ninewells Hospital, Dundee, UK.We recruited 432 patients with clinically confirmed bronchiectasis, as diagnosed by high-resolution computed tomography. After excluding days with missing air pollution data, the final model for particles with a 50% cut-off aerodynamic diameter of 10 µm (PM10) was based on 6741 exacerbations from 430 patients and for nitrogen dioxide (NO2) it included 6248 exacerbations from 426 patients. For each 10 µg·m-³ increase in PM10 and NO2, the risk of having an exacerbation that same day increased significantly by 4.5% (95% CI 0.9-8.3) and 3.2% (95% CI 0.7-5.8) respectively. The overall (lag zero to four) increase in risk of exacerbation for a 10 μg·m-3 increase in air pollutant concentration was 11.2% (95% CI 6.0-16.8) for PM10 and 4.7% (95% CI 0.1-9.5) for NO2 Subanalysis showed higher relative risks during spring (PM10 1.198 (95% CI 1.102-1.303), NO2 1.146 (95% CI 1.035-1.268)) and summer (PM10 2.142 (95% CI 1.785-2.570), NO2 1.352 (95% CI 1.140-1.602)) when outdoor air pollution exposure would be expected to be highest.In conclusion, acute air pollution fluctuations are associated with increased exacerbation risk in bronchiectasis.
Copyright ©ERS 2018.
Conflict of interest statement
Conflict of interest: A.T. Hill reports personal fees for advisory board activities from Bayer, outside the submitted work. J.D. Chalmers reports grants from GlaxoSmithKline, grants and personal fees from Boehringer Ingelheim, Pfizer, AstraZeneca and Bayer Healthcare, and personal fees from Grifols and Chiesi, outside the submitted work. P.C. Goeminne reports personal fees for lecturing from AstraZeneca, personal fees for lecturing and support for attending conferences from Chiesi, Boehringer and Bayer, and support for attending conferences from Pfizer, outside the submitted work.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical